{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:38:38Z","timestamp":1772606318601,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T00:00:00Z","timestamp":1250121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aim:\u2002<\/jats:bold> This study assesses the impact of serum carboxy\u2010terminal collagen crosslinks (CTX) bone marker feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> This was a 12\u2010month (6\u2010monthly phased), randomized, prospective, open\u2010label, multi\u2010center study conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (\u2264\u200385\u2003years old) who were na\u00efve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at 3\u2003months versus no\u2010BMF. Once\u2010monthly 150\u2003mg ibandronate tablet was administered for 12\u2003months and adherence to therapy was assessed at 6 and 12\u2003months. In addition, patient satisfaction and safety of ibandronate treatment were also assessed.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Serum CTX BMF at 3\u2003months showed no impact on adherence. The proportions of adherent patients were comparable in the BMF versus no\u2010BMF arms (92.6%<jats:italic>vs.<\/jats:italic> 96.0%, <jats:italic>P<\/jats:italic>\u2003=\u20030.16); overall, serum CTX levels were similar for adherent and non\u2010adherent patients. However, BMF patients felt more informed about their osteoporosis (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) and more satisfied (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01) than no\u2010BMF patients.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once\u2010monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence, but increased treatment satisfaction.<\/jats:p>","DOI":"10.1111\/j.1756-185x.2009.01413.x","type":"journal-article","created":{"date-parts":[[2009,8,14]],"date-time":"2009-08-14T00:02:55Z","timestamp":1250208175000},"page":"216-224","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women"],"prefix":"10.1111","volume":"12","author":[{"family":"THE BonAdASIA STUDY GROUP","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,8,13]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08657-9"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08827-X"},{"key":"e_1_2_6_4_2","first-page":"M406","article-title":"Compliance with alendronate treatment in an osteoporosis clinic","volume":"15","author":"Lombas C","year":"2000","journal-title":"J Bone Miner Res"},{"key":"e_1_2_6_5_2","first-page":"S48","article-title":"Adherence to osteoporosis therapies","volume":"12","author":"Finigan J","year":"2001","journal-title":"Osteoporos Int"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1652-z"},{"key":"e_1_2_6_7_2","article-title":"Clinical and economic impact of adherence to osteoporosis medication","volume":"14","author":"Caro JJ","year":"2003","journal-title":"Osteoporos Int"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1571-4"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030897"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(02)00946-8"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-002-1370-3"},{"key":"e_1_2_6_12_2","unstructured":"World Health Organization(2003)Adherence to long\u2010term therapies. Evidence for action. WHO\/MNC\/03.01."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070002"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070088"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070004"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(02)00728-7"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-42"},{"key":"e_1_2_6_18_2","unstructured":"F Hoffmann\u2010La Roche Ltd.MEDTAP Institute at United Biosource Corp. OPPS Scoring guideline Version 2.0 as of 08.09.05."},{"key":"e_1_2_6_19_2","first-page":"1","article-title":"Prevention and management of osteoporosis","volume":"921","author":"World Health Organization","year":"2003","journal-title":"World Health Organ Tech Rep Ser"},{"key":"e_1_2_6_20_2","unstructured":"ReginsterJY LecartMP(2004)Treatment of osteoporosis with bisphosphonates \u2013 do compliance and persistence matter?Business Briefing: Long\u2010term Healthcare1\u20139."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2004.02.005"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.20.2414"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030501"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1526"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X242890"},{"issue":"1","key":"e_1_2_6_26_2","article-title":"Women with postmenopausal osteoporosis or osteopenia previously receiving weekly alendronate or risedronate are more satisfied with monthly ibandronate","volume":"80","author":"Bonnick SL","year":"2007","journal-title":"Calcif Tissue Int"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X74862"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050313"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2009.01413.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2009.01413.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T12:54:35Z","timestamp":1697028875000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2009.01413.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,13]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1756-185X.2009.01413.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2009.01413.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,13]]},"assertion":[{"value":"2009-08-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}